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Glycogen synthase kinase-3 (GSK-3) regulates multiple cellular processes, and its dysregulation is implicated in the pathogenesis
of diverse diseases. In this paper we will focus on the dysfunction of GSK-3 in Alzheimer’s disease and Parkinson’s disease.
Speciﬁcally, GSK-3 is known to interact with tau, β-amyloid (Aβ), and α-synuclein, and as such may be crucially involved in both
diseases. Aβ production, for example, is regulated by GSK-3, and its toxicity is mediated by GSK-induced tau phosphorylation
and degeneration. α-synuclein is a substrate for GSK-3 and GSK-3 inhibition protects against Parkinsonian toxins. Lithium,
a GSK-3 inhibitor, has also been shown to aﬀect tau, Aβ,a n dα-synuclein in cell culture, and transgenic animal models.
Thus, understanding the role of GSK-3 in neurodegenerative diseases will enhance our understanding of the basic mechanisms
underlying the pathogenesis of these disorders and also facilitate the identiﬁcation of new therapeutic avenues.
1. Introduction: GSK-3 Isoforms, Expression,
andNeuronal Regulation
Glycogen synthase kinase-3 (GSK-3) is a cellular ser-
ine/threonineproteinkinase[1,2],belongingtotheglycogen
synthase kinase family [1]. It is involved in a number of
cellular processes, including the division, proliferation,
diﬀerentiation, and adhesion of cells [3]. Dysfunction of
GSK-3 is implicated in diverse human diseases, including
Alzheimer’s disease (AD), Parkinson’s Disease (PD), type
2 diabetes, bipolar disorder (BPD), and cancer [3, 4]. Two
isoforms of GSK-3 have been identiﬁed, namely, GSK-3α
and GSK-3β, which although encoded by diﬀerent genes are
similarly regulated [5]. GSK-3α (51kDa) diﬀers to GSK-3β
(47kDa) in that the former has a glycine-rich extension at
the amino-terminal end of the protein [5]. Both isoforms
are ubiquitously expressed throughout the brain, with high
levelsofexpressionseeninthehippocampus,cerebralcortex,
and the Purkinje cells of the cerebellum [6]. The expression
ratio of these isoforms, however, favors GSK-3β [6, 7].
The crystal structure of GSK-3β reveals a catalytically
active dimer [8] conformation that progressively phos-
phorylates substrates with Ser/Thr pentad repeats [9].
Despite having disparate sequences, the isoforms have a
conserved functional domain and share similar substrates,
while remaining pharmacologically distinguishable [3]. The
independentdeletionofGSK-3isoformsinmiceresultedina
distinct proﬁle of substrate phosphorylation [10], suggesting
diﬀerent functions of GSK-3 isoforms in the brain.
The activity of GSK-3 is dependent on phosphorylation
at speciﬁc sites; phosphorylation of Ser9 of GSK-3β,o rS e r 2 1
of GSK-3α, inhibits activity [9], whereas phosphorylation
of Tyr216 on GSK-3β and Tyr279 on GSK-3α increases
activity[3].ItisthoughtthatdeactivationofGSK-3hasmore
inﬂuence on activity rather than activation, as the enzyme
is constitutively active and the activation sites can undergo
autophosphorylation [11].
The most well-studied GSK-3 regulation pathway is
throughAktactivation.Insulinstimulation,forexample,can
activate phosphatidylinositol 3-kinase (PI3K), which phos-
phorylates Akt (protein kinase B) and in turn inhibits
GSK-3 [12–15]. A brief exposure to insulin, however, can
also transiently activate GSK-3β by phosphorylating Tyr216
through Fyn, a nonreceptor tyrosine kinase [13]. Other
kinases, such as protein kinase C (PKC), inhibit GSK-3
activity by phosphorylating Ser9 [14, 16, 17]. The inhibition2 International Journal of Alzheimer’s Disease
by PKC is additive to the inhibition by PI3K [14]. Addition-
ally, within the brain, p38 mitogen-activated protein kinase
(MAPK) inactivates GSK-3β by direct phosphorylation at its
C-terminus [18].
Dephosphorylation of GSK-3 at inhibitory sites (thus
activating the protein), is coordinated by protein phos-
phatase 1 (PP1), protein phosphatase 2A (PP2A), and
protein phosphatase 2B (PP2B, calcineurin) [19–21]. PP1
preferentially acts as a phosphatase for GSK-3β, while PP2A
favors GSK-3α [19]. On the other hand, the overexpression
of GSK-3β inhibits PP2A, which may serve as a negative
feedback mechanism for GSK-3β activity [22]. GSK-3 and
its complex regulatory mechanisms have been extensively
studied in a number of neurodegenerative diseases as
outlined below.
2.GSK-3 inAD andTauopathies
Alzheimer’s disease is characterized by the accumulation of
extracellular senile plaques and intracellular neuroﬁbrillary
tangles (NFTs) within the brain (for a review, see [23]). The
major component of the plaques, which was ﬁrst puriﬁed
and identiﬁed from AD brains in the 1980s [24] and later
shown to be a product of normal cellular metabolism [25],
is β-amyloid (Aβ). Aβ is proteolytically processed from
the amyloid precursor protein (APP) [26]v i ac l e a v a g ea t
the β-secretase site by BACE1 [27], followed by γ-secretase
cleavage by presenilin (PS) [28]. The key component of the
NFTs on the other hand, is the tau protein [29–31], which
was originally identiﬁed as an intracellular microtubule
stabilizer[32].BothAβ andtauare,therefore,fundamentally
involved in driving the pathogenesis of AD. With respect
to this paper then, it is of note that both these proteins
may be modulated by GSK-3. The most well-characterised
interactions, however, occur with tau.
2.1. Tau. GSK-3 is one of the main kinases involved in
the phosphorylation of tau, a process that is crucial to the
function of the protein. The normal phosphorylation of
tau determines its aﬃnity for microtubule binding [29, 33–
35], with pathological hyperphosphorylation resulting in the
dissociation of tau from microtubules and subsequent aggre-
gation to form NFTs (for a review, see [36]). GSK-3β has
beenfoundtobeassociatedwithnormalmicrotubule-bound
tau[37]aswellaswiththehyperphosphorylatedtaudeposits
in the AD brain [38, 39]. There are several lines of evidence
that support a direct functional link between tau phosphory-
lation and GSK-3. For example, in vitro and in cell culture
models, both GSK-3α and GSK-3β can phosphorylate tau
at various sites that are consistent with the epitopes found
to be hyperphosphorylated in AD brains [40–45]. The over-
expression of GSK-3β in animal models also promotes the
phosphorylation oftau,implicating itasan in vivo taukinase
[46–49]. Conversely, the inhibition of GSK-3β activity by
either GSK-3 inhibitors or upstream Akt inhibitors reduces
tau phosphorylation [50–58]. GSK-3β thus aﬀects tau func-
tion through interfering with tau phosphorylation, thereby
disrupting microtubule stability [59, 60], self-assembly of
microtubules [61, 62], the microtubule-dependent cell
processes [63], and regulation of organelle transport and
axonal transportation [64–66]. Interestingly, the overexpres-
sionoftaualsoincreasedGSK-3βactivity,whichperpetuated
the phosphorylation of tau [67].
In addition to eﬀects on phosphorylation, the activa-
tion of GSK-3β may also facilitate the aggregation of tau
[68–71]. Furthermore, the in vivo overexpression of GSK-3β
accelerates tau-induced neurodegeneration [47, 49, 71, 72],
while the inhibition of its activity reduces tau toxicity [73–
75]. Conversely, in the absence of tau, the neurodegenerative
and cognitive phenotype observed in GSK3-overexpresing
mice is ameliorated, suggesting that tau may mediate GSK-
3β toxicity [76]. In addition, GSK-3 may regulate tau-mRNA
splicing [77] and expression [78] by disrupting transcription
[79].
2.2. β-Amyloid. Accumulating evidence suggests that GSK-
3 interferes with the biology of Aβ, which is believed to
be upstream of tau in the pathogenesis of AD [23]. Aβ
accelerates tau pathology [80, 81] and promotes tau phos-
phorylation by several mechanisms, including activation of
GSK-3β [82–84]. The use of Aβ antibodies both in vitro and
in vivo decreases GSK-3 activity, supporting the interaction
between Aβ and GSK-3 [85]. It has also been shown that
the activation of GSK by Aβ in primary hippocampal
cultures is speciﬁc to GSK-3β [86], and that the inhibition
of GSK-3β prevents Aβ-induced toxicity to neurons [82,
84, 87, 88]. Likewise, although both isoforms of GSK-3 are
hyperactivated in transgenic mice expressing mutant APP
(V717I) [89], the data from this model together with that
from a model expressing the intracellular domain of APP
[90] ﬁrmly support the notion that it is the activation of
GSK-3β by amyloid that results in downstream pathological
eﬀects on tau. The Aβ-induced activation of GSK-3 also only
needs to be transient to result in tau hyperphosphorylation
and other eﬀects such as mitochondrial traﬃcking impair-
ments [91]. Finally, tau null mice are protected against Aβ-
induced toxicity [92, 93] and GSK-induced toxicity [76],
which taken together with the discussed data highlight the
complex interaction between GSK, Aβ, and tau. This is
furthercomplicatedbythefactthatGSK-3isinvolvedinAPP
processing and subsequent Aβ production.
The amyloid precursor protein and PS1 are substrates of
GSK-3 [94–98], and GSK-3α is thought to regulate Aβ pro-
duction by interfering with APP cleavage at the γ-secretase
step [99]. Co-overexpression of GSK-3α and APP in CHO
cells increased the level of Aβ in a dose-dependent manner,
while selective reduction of GSK-3α protein expression by
RNAi decreased Aβ levels [99]. Although Phiel et al. [99]
showed an opposite role of GSK-3β in their study, GSK-
3β was later shown to decrease Aβ levels by an unknown
pathway [100]. Nevertheless, the genetic or pharmacological
deactivation of GSK-3 reduces Aβ and its associated toxicity,
ameliorates Aβ-induced behavioral deﬁcits, and rescues
neuronal loss in APP-overexpressing mouse models [101–
103], thus strongly implicating GSK-3 in the pathogenesis of
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3. GSK-3 inParkinson’s Disease
Parkinson’s disease is characterized by dopaminergic neuron
degeneration in the substantia nigra pars compacta (SNpc)
with Lewy body (LB) pathology, accompanied by clinically
deﬁned parkinsonism [104]. As there is a potential role of
tau emerging in PD [105–107], then the function of GSK-3
in PD has also thus been investigated. The examination of
postmortem tissue from PD patients has revealed that GSK-
3β,phosphorylatedatSer9,isspeciﬁcallylocalisedwithinthe
halo of LBs [108] and that GSK-3β activity is also elevated in
the striatum [109]. This latter ﬁnding has been recapitulated
i nm o u s em o d e l so fP D[ 110]. Increased GSK-3 levels have
also been reported in peripheral blood lymphocytes in PD
patients [111], and polymorphisms in GSK-3β, which aﬀect
its transcription and splicing, are also associated with disease
risk in PD when stratifying by tau haplotype [112, 113].
Mechanistically there is evidence to support an inter-
action between α-synuclein, a 16kDa natively unstructured
protein that is fundamentally involved in the pathogenesis of
PD, and GSK. Aggregated α-synuclein species are the main
component of LBs and single nucleotide polymorphisms
and duplication or triplication of the α-synuclein gene
cause familial Parkinsonian degeneration [104]. α-synuclein,
w h i c hi sas u b s t r a t ef o rG S K - 3 β phosphorylation, may
also modulate the activation of GSK-3β [114]; GSK-3β
phosphorylation at Tyr216 (which activates GSK-3 activity)
is also abolished in cells lacking α-synuclein and in α-
synuclein knockout mice [110]. The potential role of GSK-
3β in PD has been elucidated in the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) model of PD, where the
inhibition of GSK-3β protects against MPTP toxicity in vitro
and in vivo [56, 110, 115] and decreases α-synuclein protein
expression[56].Takentogether,thesedatastronglyimplicate
GSK-3 in the pathogenesis of PD. The neuroprotective
possibilities of GSK-3 inhibition on Aβ, tau and α-synuclein
pathologyhavethusbeenexploredindepth,mostextensively
with lithium.
4. Lithium:A GSK-3 Inhibitor
Lithium, a monovalent cation, aﬀects multiple cellular
processes in model organisms and humans (for a review, see
[116]). Importantly, it has been used as a mood stabilizer
and primary therapy for BPD since its discovery by Cade
in 1949 [117]. Although eﬀective in many cases, lithium
exhibits a narrow therapeutic window, and side eﬀects may
occur within the therapeutic dose range [118]. Lithium is
suggested to have several molecular targets in BPD, one
leading mechanism of action is the inhibition of GSK-3
[116].
Haplo-insuﬃciency of GSK-3β mimics behavioral and
molecular eﬀects of lithium [119], while GSK-3β over-
expression mimics mania and hyperactivity in a mouse
model [120], supporting GSK-3β as a relevant target of
lithium action [121]. With an inhibitory Ki of 2mM [121],
lithium inhibits both GSK-3α and GSK-3β directly through
competitive inhibition of Mg2+ [122], and indirectly through
themodulationofpost-translationalmodiﬁcationsofGSK-3
[123, 124]i nan u m b e ro fs p e c i e s[ 125]. Lithium is selective
for GSK-3α and GSK-3β and does not inhibit other protein
kinases tested in vitro and in vivo, including casein kinase II,
protein kinase A and C, MAPK, and CDK5 [121, 126]. When
utilized at therapeutic concentrations in various cell culture
models, lithium reduces tau phosphorylation [53, 127–129]
and the processing of APP to generate Aβ [99, 130, 131],
suggesting that lithium may have important implications in
both AD and BPD. However, some of these ﬁndings have
been disputed, with lithium shown to increase β-secretase
activity and to subsequently elevate extracellular Aβ levels
in CHO cells and rat cortical neurons [132]. In this case,
the activity of γ-secretase was unaltered, suggesting that the
lithium-induced elevation of Aβ was independent of GSK-
3 inhibition [132]. In addition, lithium treatment has been
shown to reduce tau protein and mRNA levels in cultured
cortical neurons [79].
Nevertheless, lithium has been assessed for its potential
eﬃcacy in treating “AD-like” pathology in vivo. In wild-type
rats, lithium has been shown to reduce tau phosphorylation
and inhibit GSK-3 activity [133] and to also enhance spatial
memory [134, 135]. Using transgenic animals characterised
by progressive Aβ deposition, lithium treatment has been
consistently found to decrease Aβ levels and APP phos-
phorylation, as well as to reduce GSK-3 activity and tau
phosphorylation [99, 101, 136–138]. In contrast to previous
cell culture studies, however, β-secretase activity has been
unaﬀected [101, 132]. Lithium treatment has also been
shown to prevent Aβ toxicity [136], preserve dendritic
structure [101], facilitate neurogenesis [138], and rescue Aβ-
induced cognitive impairment [101, 137, 138].
Less clear, however, is the eﬃcacy of lithium against
tau-mediated degeneration. Mice that overexpress disease-
linked tau exhibit reduced tau phosphorylation with lithium
treatment [55, 73–75, 139]. In addition, tau transgenic
models have attenuated axonal degeneration with lithium
treatment [55], but no motor or working memory recovery
[139]. Lithium-treated 3XTg mice (harbouring both tau
and Aβ pathology) have reduced GSK-3 activity and tau
phosphorylation, but no change in Aβ levels or working
memory [126]. However, in accordance with cell culture
studies [53, 127–129] GSK-3 activity remained the same in a
long-term (5 months) lithium trial [74], possibly suggesting
that the protection oﬀered by lithium is GSK-3 independent.
Theauthors[74]alternativelysuggestedthatlithiumreduced
the tau lesion primarily by promoting its ubiquitination and
degradation rather than by inhibiting its phosphorylation
through GSK-3.
While these in vitro and in vivo studies reveal a beneﬁcial
eﬀect of lithium on tau and Aβ pathology, a number
of observational studies and case reports have provided
conﬂicting evidence, with both positive [140–144]a n d
negative outcomes [145, 146] on dementia reported. Despite
this, lithium has recently been evaluated as a therapy for
AD in a 10-week multicenter, randomized, single-blind, and
placebo-controlledtrial[147].GSK-3activitywasmonitored
in lymphocytes at 1-2 week intervals, total and phospho-
rylated tau levels were assessed in the CSF, and Aβ(1−42)
levels were assessed in the CSF and plasma at the end of4 International Journal of Alzheimer’s Disease
treatment. Cognitive function was assessed using the Mini-
Mental State Examination (MMSE), the Alzheimer’s disease
Assessment Scale-Cognitive subscale (ADAS-Cog) and the
Neuropsychiatric Inventory (NPI). The study concluded that
lithium was not an eﬀective therapeutic for AD, as there were
no signiﬁcant eﬀects on any of the endpoint measurements.
A post-hoc examination on a subset of individuals did,
however,revealanincreaseinserumBDNFthatwasinversely
correlated with decreased ADAS-Cog sum scores [148].
Further long-term studies are required to determine the
safety and eﬃciency of lithium or other GSK-3 inhibitors for
the treatment of AD.
In pursuit of GSK-3 regulation in PD, lithium has also
been tested in animal models of this disease. The data,
however, are not conclusive, with lithium shown to both
protectagainstthedopaminedepletionresultingfromMPTP
toxicity [149] and to also cause a decrease in brain dopamine
(DA) release [150] that leads to deﬁcits in DA levels
[151]. Furthermore, lithium treatment does not prevent
dopaminergic neuron loss in the related 6-OHDA model
of PD [152]. There is, therefore, currently little evidence to
support lithium as a treatment strategy for PD. The data
on the use of lithium in other human neurodegenerative
diseases is also not compelling.
Lithium, for example, has also been investigated as a
therapy for one of the motor-neuron diseases, amyotrophic
lateral sclerosis (ALS), despite the lack of an established
connection with GSK-3. Although lithium was found to
delay disease onset and to reduce neurological deﬁcits in
both ALS mouse models and a small human trial [153, 154],
other mouse and human trials have shown detrimental
eﬀects [155, 156]. The potential utility of lithium in ALS, or
indeed in any of the neurodegenerative disorders outlined
above, remains unclear. It is likely that lithium has other
activities, independent of GSK-3, that may mediate its
pharmacodynamics.
5. Concluding Remarks
We have summarized the latest knowledge regarding GSK-
3 and its involvement in neurodegenerative diseases such
as AD and PD. Although extensive research has been
undertaken in the last decade, the role of GSK-3 in disease
pathogenesis has yet to be fully elucidated. The inhibition
of GSK-3 may be a potential target for AD, since it has
regulatory eﬀects on both Aβ and tau. Similarly, GSK-
3 inhibition could interact with α-synuclein to aﬀect the
pathogenesis of PD. The intriguing preclinical data, however,
hasyettobetranslatedintoaneﬀectivepharmacotherapyfor
neurodegeneration, perhaps in part owing to the complex
regulation of GSK and its activity on multiple substrates.
Future endeavors should investigate alternative modulators
of GSK-3 and annotate more precise mechanisms of how the
isoforms of GSK-3 participate in neurodegeneration.
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